Skip to content
Back to meeting Original
Ana I. Velázquez Mañana, MD, MSc, FASCO· @AnaVManana · X·· 1 day agoScore70
Body

✨ PRACTICE CHANGING ✨ data from #ESMO26

Divarasib becomes the NEW Standard of Care for 2L KRAS G12C #LungCancer

@FSkoulidis presents results from Krascendo 1

Divarasib significantly prolongs PFS and OS with a more tolerable safety profile

11 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

Source: Ana I. Velázquez Mañana, MD, MSc, FASCO · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.